Large animal models for translational research in acute kidney injury

Balamurugan Packialakshmi, Ian J. Stewart, David M. Burmeister, Kevin K. Chung and Xiaoming Zhou

Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

ABSTRACT
While extensive research using animal models has improved the understanding of acute kidney injury (AKI), this knowledge has not been translated into effective treatments. Many promising interventions for AKI identified in mice and rats have not been validated in subsequent clinical trials. As a result, the mortality rate of AKI patients remains high. Inflammation plays a fundamental role in the pathogenesis of AKI, and one reason for the failure to translate promising therapeutics may lie in the profound difference between the immune systems of rodents and humans. The immune systems of large animals such as swine, nonhuman primates, sheep, dogs and cats, more closely resemble the human immune system. Therefore, in the absence of a basic understanding of the pathophysiology of human AKI, large animals are attractive models to test novel interventions. However, there is a lack of reviews on large animal models for AKI in the literature. In this review, we will first highlight differences in innate and adaptive immunities among rodents, large animals, and humans in relation to AKI. After illustrating the potential merits of large animals in testing therapies for AKI, we will summarize the current state of the evidence in terms of what therapeutics have been tested in large animal models. The aim of this review is not to suggest that murine models are not valid to study AKI. Instead, our objective is to demonstrate that large animal models can serve as valuable and complementary tools in translating potential therapeutics into clinical practice.

Abbreviations: AKI: acute kidney injury; DAMPs: Danger-associated molecular patterns; GFR: Glomerular filtration rate; iNOS: Inducible nitric oxide synthases; I/R: Ischemia reperfusion; IRI: Ischemia reperfusion injury; LAM: Large animal models; LPS: Lipopolysaccharides; MSC: Mesenchymal stem cell; NHP: Nonhuman primates; NO: Nitric oxide; PAMPs: Pathogen-associated molecular patterns; PRR: Pattern recognition receptors; TLR: Toll-like receptors

Introduction
Acute kidney injury (AKI) is defined by a sudden reduction in renal function and is associated with mortality in observational studies. For example, one study of combat casualties found that AKI was independently associated with mortality after adjustment for demographics, hemodynamics, and injury severity [1]. Furthermore, AKI has been associated with long-term complications to include chronic kidney disease [2], end stage kidney disease [2], hypertension [3,4], heart failure [5,6], and mortality [7,8]. Both local and systemic inflammation play an essential role in the pathogenesis of AKI. Despite extensive research and significant progress made in understanding basic mechanisms for the disease in rodent models, no clinically proven interventions exist to prevent AKI, accelerate recovery of AKI, or reduce progression of AKI to CKD in patients [9].

Owing to their ease of handling, breeding, and genetic modification, mice and rats are often chosen to study the basic mechanisms of AKI and to evaluate potential therapeutics. However, many promising interventions for AKI found in mice and rats have not been reproduced in clinical trials. For example, N-acetylcysteine has been demonstrated to prevent AKI induced by ischemia/reperfusion (I/R) [10], sepsis [11], rhabdomyolysis [12], and contrast medium [13] in rodents, but failed to prevent AKI induced by contrast [14], vancomycin [15], and I/R following cardiac surgery [16–18] in clinical trials. Many reasons are postulated for the failure to transition therapeutics from animal models to clinical practice [19,20], but one factor is that rodents and humans have developed different innate and adaptive immune systems, since they diverged somewhere between 65 and 75 million years ago. For instance,
Overview of molecular mechanisms of AKI

The most common cause of AKI is ischemia–reperfusion injury (IRI) induced by transplantation, trauma, burns, or sepsis, that leads to a reduction of renal blood flow. The second most common cause is certain medications and toxins [26,27]. Regardless of the initial insult, however, these different causes share some common pathophysiology. While the exact sequence of events can differ, the pathophysiology includes inflammation, immune damage, oxidative stress, reduction in renal perfusion, and both apoptotic and necrotic cell death [28–31]. Following the insult, damaged cells in the kidney and/or other tissues release danger-associated molecular patterns (DAMPs), such as high mobility group box-1, S100A8, fibronectin, and DNA. In the case of sepsis-induced AKI, pathogens release pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides (LPS). The released DAMPs and PAMPs then bind pattern recognition receptors (PRR), including Toll-like receptors (TLR), on the surface of kidney cells and leukocytes and activate NF-κB and other pro-inflammatory transcription factors. This results in the release of cytokines and chemokines with subsequent adhesion and infiltration of leukocytes into the renal parenchyma, culminating in endothelial dysfunction, impaired mitochondrial function, disturbed redox balance, epithelial apoptosis, and necrosis. After these pathologic changes reach a threshold, kidney function is compromised as evidenced clinically by oliguria as well as increases in serum creatinine and blood urea nitrogen [28,31–33].

The differences in innate immunity among rodents, large animals, and humans

Given the acute nature of AKI, innate immunity is a predominant driving factor in its pathophysiology. Innate immunity is composed of soluble molecule-mediated immunity and cell-mediated immunity. The former includes complement, cytokines, and chemokines, while the latter includes macrophages, neutrophils, natural killer, and dendritic cells [34,35]. The infiltration of innate immune cells into the kidney is coordinated by a large array of chemokines. It has been reported that the chemokines CCL24/CCL26, CXCL8/IL-8, CXCL7, CXCL11, CCL13, CCL14, CCL15, CCL18, and CCL23 and are present in humans, but not in mice. Conversely, CCL12, CCL6, CCL9, and CXCL15 have been identified in mice, but not in humans [21]. Some of these chemokines have been demonstrated to be important for the development of AKI. For example, CCL24/CCL26 is increased in patients with subclinical and clinical rejection of kidney allograft in patients [36].

Neutrophils are the most abundant type of granulocytes and make up 40–70% of all white blood cells in humans. They are also the most abundant leukocytes infiltrating the kidney immediately after IRI [37]. Neutrophils produce and secrete cytotoxic compounds such as reactive oxygen species, while adhering to the endothelium and extravagating into the affected renal tissue. CXCL8/IL-8 is the primary chemotactant for human neutrophil recruitment. Serum CXCL8/IL-8 levels predict AKI in patients with acute pancreatitis [38], after cardiac surgery [39] and liver transplantation [40]. Conversely, CCL12 probably mediates tubular regeneration and functional recovery from cisplatin-induced AKI following inhibition of dipeptidyl peptidase-4 in a murine model [41]. Given the important roles that these molecular pathways play in the development of AKI, it becomes apparent that immunomodulatory findings from rodent AKI models may have certain limitations [19].

Macrophages are the most abundant immune cells within the kidney, but monocytes are rare in the healthy kidney. After recruitment into the injured kidney, monocytes differentiate into proinflammatory M1 and/or immune-regulatory M2 types of macrophages...
Although the exact stimuli and mechanisms causing differentiation into M1 versus M2 macrophages remain unclear, binding of DAMPs and PAMPs to PRR induces activation of M1 macrophages from both resident and differentiated macrophages. Activated M1 macrophages then secrete proinflammatory cytokines such as IL-1β, IL-6, IL-12, IL-18, and TNF-α, and release reactive oxygen and nitrogen species, which contribute to AKI. M2 macrophages release anti-inflammatory mediators such as IL-10 and TGF-β, limiting inflammatory responses in the kidney. Inducible nitric oxide synthase (iNOS) is the primary source of reactive nitrogen species in macrophages in mice [34,43]. In murine macrophages, iNOS is up-regulated by several orders of magnitude upon incubation with IFN-γ or LPS. In contrast, iNOS is not generally present in human macrophages; although there are some reports showing expression of iNOS under severe disease conditions [44]. Instead, IFN-γ and LPS stimulate indoleamine 2,3-dioxygenase (IDO), an anti-inflammatory enzyme, in human macrophages [44]. Furthermore, the lethal dose of LPS for mice is about 1000 times higher than that for humans [44].

These differences must be taken into consideration when translating potential therapeutic candidates that target macrophages which have been identified in murine models. For example, Rasburicase prevents cisplatin-induced AKI in rats in part through reduction of macrophage infiltration [45]. However, it failed to prevent AKI after cardiovascular surgery in patients [46]. Probiotics ameliorate I/R-induced AKI by increasing M2 macrophages in rats [47]. However, it has been demonstrated that the density of CD163+ M2 macrophages in the human kidney correlates with the severity of a variety of renal diseases, including: AKI [48], acute tubular injury [49], IgA nephropathy [50], chronic kidney allograft injury [51], and lupus nephritis [52]. Moreover, erythropoietin prevents AKI in various murine models in part by reducing the infiltration of macrophages and promoting M2 macrophage phenotype [20,53]. However, it has failed in the majority of clinical studies [20,44].

In contrast to rodents, the immune systems of large animal animals are more analogous to humans. Similar to humans, dogs and pigs have intralobular lymphatics, which is absent or not yet defined in mice [54]. Among LAM, pigs are the most popular large animals used in the kidney research (Figure 1). Pigs share more than 80% of immune parameters with humans as compared to mice that share less than 10% [22,23,55]. Similar to humans, and in contrast to mice, pigs have a high percentage of neutrophils in the peripheral blood (50–70%), express CXCL8/IL-8, do not express iNOS in macrophages, IFN-γ and LPS stimulate IDO in macrophages, and pigs are sensitive to endotoxin shock [23,56]. As in humans, expression of CXCL-8/IL-8 and infiltration of M2 macrophages correlate with disease severity in pigs. This is evidenced by studies in swine showing that attenuation of burn- and trauma-induced AKI by oral resuscitation and vitamin C is associated with a reduction of serum levels of CXCL-8/IL-8 [57,58] and that mitigation of I/R-induced AKI by inhibiting complement pathway is associated with decrease of infiltration of CD163+ M2 macrophages into the kidney [59].

TLR4, the receptor for LPS, is arguably the most important receptor of PRR. Swine and human TLR4 genes have approximately 83% sequence homology in three exon sequences as opposed to 75% between humans and mice. Overall, the porcine TLR4 promoter

---

**Figure 1.** Large animal models in kidney research indexed in the PubMed from 1970 to 2019. (Year X-axis) retrieved using a search query: ‘(renal’ OR ‘kidney’) AND (‘species name’) on May 20, 2020. The overall trend shows the preference for porcine models.
The differences in adaptive immunity among rodents, large animals, and humans

Adaptive immunity is mediated by T and B lymphocytes. Although there is some discrepancy, the majority of studies have demonstrated or suggested that CD4⁺ T cells are a factor in driving the initial phase of AKI in murine models, whereas the roles of cytotoxic T cells and B cells remain unclear [64]. Whether CD4⁺ T cells are involved in human AKI is unknown, but in pig models of renal autotransplantation, addition of polyethylene glycol, trimetazidine, and/or an inhibitor of complement to preservation solutions decreases infiltration of macrophages and T or CD4⁺ T cells into the kidney, and results in reduced graft injury [65–68]. Depending on inducers, CD4⁺ T cells can be activated and differentiated into different subsets including pro-inflammatory Th1 and Th17 cells and regulatory T cells (Treg) [64]. In rodents, both Th1 and Th17 subsets contribute to AKI through secreting pro-inflammatory cytokines and recruiting other types of pro-inflammatory cells into the kidney, whereas Treg cells protect the kidney from IRI and help resolution of AKI by limiting inflammation [64,69,70].

An important difference in CD4⁺ T cell activation exists between mice and humans. In order to fully activate CD4⁺ T cells, the costimulatory receptor CD28 has to be activated. Nearly all mouse CD4⁺ T cells express CD28, whereas only 80% of human CD4⁺ T cells express CD28 on their surface [21]. Several studies have shown that blocking the CD28 costimulatory pathway with CTLA-4 Ig decreases infiltration of monocytes and ameliorates I/R-induced AKI in rodents [71–73]. However, CTLA-4 Ig does not significantly affect human Th1 cells in renal graft tissue [74]. Moreover, immunotherapy with CTLA-4 antibodies causes AKI in some cancer patients [75,76].

Differences also exist at the differentiation and phenotypic levels between rodent and human T cells. In humans, type I interferon IFN-α stimulates Th1 differentiation, whereas it does not in mice [21]. The human Th17 cells express surface CCR2, whereas mouse Th17 cells express CCR7 instead [77]. Human Th17 cells have multiple subsets, whereas similar subsets exist in rodents is not clear [78,79]. Mouse immune tolerance is a poor predictor of human tolerance [80]. However, this gap can be alleviated by NHP Treg cells, which display phenotypic and functional similarities with human Treg cells [81]. Taken together, differences in immunology between humans and mice may help explain the lack of successful pharmacotherapies for AKI in patients.

The differences in gut microbiota among rodents, large animals, and humans

Gut microbiota regulates immune responses in pre-clinical models and humans [82,83]. Emerging evidence indicates that gut microbiota also plays a critical role in modulating various renal diseases [84,85]. The majority of our current knowledge of the effects of gut microbiota on AKI is from studies using mice and rats, and data from LAM studies are scarce [85–87]. There is a positive correlation between gut Rothia and Staphylococcus levels and renal function in a rat I/R AKI model [88]. Depending on experimental contexts, both reno-protective and reno-harmful effects of gut microbiota have been reported. Germ-free mice have an unexpectedly high frequency of natural killer T cells and abundant T cells in the kidney and are prone to I/R-induced AKI [64]. In contrary, depletion of mouse gut microbiota by an antibiotic-cocktail significantly attenuates I/R-induced AKI associated with low expression of F4/80 macrophages and pro-inflammatory chemokines [89]. Intestinal microbiota modulates immune reactions in AKI through their metabolites such as short chain fatty acids, trimethylamine-N-Oxide, and D-amino acids [86,90]. While it is known that there is a gut-kidney cross talk, it has only recently been demonstrated that AKI can influence intestinal microbiomes. Traditionally, I/R-induced AKI has been regarded as sterile inflammation. However, Yang et al recently reported that I/R-induced AKI provokes intestinal dysbiosis and bacterial translocation which is associated with increases of Th1
and Th17 responses as well as activation of neutrophils and M1 macrophages in a mouse model. It is possible that the translocation of gut resident bacteria exacerbates inflammatory process in I/R-induced AKI [91].

Because gut microbiota modulate immune responses in AKI, manipulating the gut microbiota has been proposed as a possible new therapeutic avenue to treat AKI. D-serine, a gut microbiota metabolite which is decreased in AKI patients, mitigates I/R-induced AKI in mice when given orally [90]. Anticipating further studies in this area, it is important to recognize the differences amongst murine, large animal, and human gut microbiota [92]. Although mice and humans share considerable anatomical, histological, and physiological similarities of the intestinal tract, the differences in the size of intestinal tract and dietary habits contribute to only 4% of shared bacterial genes in mice and humans [93]. For example, mice harbor segmented filamentous bacteria, which have a profound effect on the maturation of innate immune system, whereas these bacteria have not been identified in human adults [93]. On the other hand, Macaca fascicularis shares 39.49% of gut microbiome genes with humans and 25.45% of the genes with pigs; this is compared with only 0.6% of the genes with mice [94]. Like humans, the pig gut microbiota mainly consists of Formicates and Bacteroidetes phyla [95]. Further, human microbiota-associated piglets have been established by inoculating microbiota from infants, children, and adults. These piglets share even more gut microbiota with humans than conventional piglets [96]. Since gut microbiota regulate immune responses, the differences in murine and human gut microbiota compositions could contribute to the differences in immune responses seen during AKI. Likewise, similarities between large animal and human microbiota may explain some of the shared characteristics in AKI-induced immune responses.

Mechanistic strategies of AKI for evaluating therapeutics in LAM

The strategies that have been evaluated to intervene on AKI in LAM are similar to those evaluated in mice and rats [30]. They include limiting inflammation, reducing oxidative stress, increasing renal blood flow, and stem cell therapy. Multiple approaches targeting various steps in immune pathways have shown promising results in LAM (Tables 1–4). They include inhibition of TNF-α by an antibody in NHP [165] and the chemical FR167653 in pigs [112], infiltration of macrophages, and T-helper cells by the chemical TBC-1269 in pigs [105], and complement cascade by compstatin CP40 in cynomolgus monkeys [153]. Erythropoietin is well known for its erythropoietic effect and was later recognized to be an anti-inflammatory cytokine. Erythropoietin acutely improves glomerular filtration rate (GFR) in pigs after IRI and reduces both renal and circulating levels of TNF-α [106]. Erythropoietin also shows a preventive effect against AKI in NHP [156]. The side effect of increased red blood cells, and higher levels of hematocrit, can be minimized by an 11 amino acid nonerythropoietic peptide (ARA290) without losing anti-inflammatory properties [109]. Further, ARA290 reduces interstitial fibrosis by decreasing α-smooth muscle actin in the porcine kidney [109]. However, only two out of nine clinical trials found the preventive effect of erythropoietin against I/R-induced AKI in patients, indicating that even LAM is not a complete replica of humans in the translational research [20].

Strategies that target the underlying cause of AKI may also be effective in inhibiting inflammation, which can potentially be discovered by the use of LAM. For example, an exciting recent avenue of interest in the trauma field involves the role of endotheliopathy in inflammatory processes [194,195]. This is mediated in part by glyocalyx shedding which predisposes the vasculature to cellular extravasation into the interstitial space. This has been examined in models of both cardiopulmonary bypass [196] and burns [197], as both renal and circulating markers of glyocalyx shedding (e.g. syndecan) are implicated in the development of AKI. In the context of burn trauma, it is known that resuscitation fluid can affect the degree of endothelial dysfunction [198]. However, it is also known that hypovolemia plays a role in burn-induced AKI, and fluid resuscitation ameliorates burn-induced AKI and is associated with decreases in IL-1β, IL-6, IFN-γ, and GM-CSF in pigs [150].

Oxidative and nitrostative stresses also mediate AKI. Sodium sulfides or hydrogen sulfide attenuate I/R-induced AKI in a porcine model by reducing nitrostative stress, lipid peroxidation, IL-1β, and IL-6 [118]. Rapamycin mitigates AKI by reducing lipid peroxidation, protein carbonylation, NF-κB and by promoting mitophagy in a mini-pig model [140]. Mitochondria are a major source of reactive oxygen species which may be ameliorated by Elamipretide, which is a mitochondria-targeted tetrapeptide. By decreasing ROS generation and stabilizing cardiolipin [199], an important component of the inner mitochondrial membrane, Elamipretide improves renal function in atherosclerotic renal artery stenosis-induced injury in domestic pigs [137].
| Model                        | Therapy                           | Therapeutic target                              | References |
|------------------------------|-----------------------------------|-------------------------------------------------|------------|
| Ischemia Reperfusion         | Doxycycline                        | MMP inhibition reduces lipid peroxidation        | [97]       |
|                              | Carbon monoxide inhalation         | Activates HSP70 response, anti-apoptosis, anti-inflammatory | [98]       |
|                              | Sitaxentan                         | Endothelin-A-receptor antagonist improves hypoxia | [99]       |
|                              | Sildenafil citrate                  | Increases NO bioavailability and reduces inflammation | [100]      |
|                              | Ulinastatin                        | Antioxidative stress, anti-inflammatory          | [101,102]  |
|                              | Alkaline phosphatase                | Diphosphorylation of signaling molecules, adenine, etc. | [103]      |
|                              | Canrenenate                        | Reduces oxidative stress                         | [104]      |
|                              | TBC-1269                           | Selectin ligand blockade prevents leucocyte adhesion | [105]      |
|                              | Erythropoietin                     | Anti-inflammatory decreases TNF-α                 | [106]      |
|                              | Erythropoietin                     | Reduces noradrenaline requirements to achieve the hemodynamic targets | [107]      |
|                              | Carbamylated erythropoietin or recombinant human erythropoietin | Failed to attenuate prolonged ischemia-induced AKI | [108]      |
|                              | ARA290, EPO derivative              | Reduces MCP-1 and IL-6 and interstitial fibrosis | [109]      |
|                              | Cyclic helix B peptide             | Antiapoptosis, tissue protection                 | [110]      |
|                              | AP214                               | α-MSH analogue, anti-inflammatory                | [111]      |
|                              | rhC1 inhibitor                     | Inhibits complement system                       | [59]       |
|                              | FR166765                           | P-38 MAPK inhibitor reduces TNF-α                | [112,113,114] |
|                              | Anti-high-mobility group box 1 antibody | Reduces blood inflammatory cytokine levels       | [115]      |
|                              | Caspase-3 siRNA                    | Inhibits apoptosis                                | [116]      |
|                              | Hemoperfusion with leucocyte-depleted blood | Inhibits inflammation and apoptosis              | [117]      |
|                              | Hydrogen or sodium sulfide         | Reduces oxidative stress, inflammatory cytokines, iNOS | [118,119]  |
|                              | Hydrogen gas                       | No effect                                        | [120]      |
|                              | Anti-CD47 antibody                 | Reduces inflammation and apoptosis               | [121]      |
|                              | Atrial natriuretic peptide         | Improves blood flow to the kidneys               | [122]      |
|                              | Fenoldopam                         | Dopamine D1 receptor agonist improves blood flow | [123]      |
|                              | NO + corticosteroids               | Reduces vascular resistance and inflammation    | [124]      |
|                              | Trimetazidine                      | Inhibits mitochondria oxidation of fatty acids   | [125]      |
|                              | Vitamins C and E                   | Antioxidant and nutrients                        | [58,126]   |
|                              | Mesenchymal stem cells             | Decreases inflammation, oxidative stress, and fibrosis | [127,128–130] |
|                              | Mitochondrial transplantation       | Reduces IL-6 expression in the renal cortex      | [131]      |
|                              | Meclizine                          | Up-regulates glycolysis and reduces oxidative stress | [132]      |
|                              | N-acetylcysteine                   | Reduces oxidative stress and improves hemodynamics | [133]      |
|                              | N-acetylcysteine                   | Reduces oxidative stress                         | [134]      |
|                              | Ascorbic acid + selenium + tocoferol and N-acetylcysteine | No effect on oxidative stress                     | [135]      |
|                              | Resveratrol                        | Decreases oxidative stress and apoptosis         | [136]      |
|                              | Elamipretide                       | Improves mitochondrial function                  | [137]      |
|                              | Danegaptide (not effective)        | Targets mitochondrial Connexin 43 channels       | [138]      |
|                              | TRVP channel inhibitor             | Increases blood flow to the kidneys              | [139]      |
|                              | Calcitonin antibodies              | Blocks the effect of calcitonin                  | [140]      |
|                              | Drugs (nephrotoxins)               | Autophagy, mitophagy, reduces ROS                | [140]      |
|                              | Rapamycin                          | Improves renal function                          | [141]      |
|                              | Magnesium                          | Autophagy activation and apoptosis inhibition     | [142]      |
|                              | Retinoic acid                      | Reduces the inflammation by targeting NLRP3 inflammasome | [143]      |
|                              | microRNA-30c (miR-30c)             | Reduces oxidative damage and enhances autophagy  | [144]      |
|                              | N-acetylcysteine                   | Inhaled nitric oxide                              | [145]      |
|                              | Rapamycin                          | Vasodilatation, reduces inflammation, counteracts prostanoid pathways | [146]      |
|                              | Elamipretide                       | Blocks calcitonin action                         | [146]      |
|                              | Polyoxymyx B hemoperfusion         | Neutralize LPS                                   | [148]      |
|                              | Peritoneal negative pressure       | Inhibits inflammation                            | [149]      |
|                              | Enteral fluid resuscitation        | Useful in a resource poor environment, reduces circulating cytokines | [150]      |
|                              | Hemorrhagic shock                  | Several treatments are combined together         | [151]      |
|                              | Aggressive care (AC)               | Terlipressin                                     | [152]      |
Increase of blood flow to the kidney by vasodilation through increasing either nitric oxide bioavailability, endothelin inhibition, or administration of hormone and neurotransmitter analogues has been shown to ameliorate AKI in LAM. By preserving nitric oxide bioavailability and preventing regional hypoxia, Sildenafil attenuates IRI in canine and swine kidneys [100,186]. Sitaxsentan, an endothelin receptor antagonist, improves hypoxia during AKI in a porcine model [99]. Sodium nitroprusside, a nitric oxide donor, in combination with N-acetyl cysteine and phosphormidon, an endothelin-1 converting enzyme inhibitor, improves renal function after I/R injury in a canine model [188].

Fenoldopam, a synthetic D1 dopamine receptor agonist, demonstrated a prophylactic benefit against the reduction in renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs [193]. Fenoldopam has also been shown to attenuate I/R-induced AKI in a porcine model [123]. Fenoldopam was found to be beneficial in the prevention or treatment of AKI in postoperative or intensive care patients [200], but a recent review only found that its renoprotective effect is transient [201]. Both atrial natriuretic peptide and brain natriuretic peptide relax vascular smooth muscles and improve blood flow and urine output in dogs [182]. Limited clinical trials suggest that low dose

---

### Table 2. Major therapeutic approaches tested in NHP models.

| Model                          | Therapy                                      | Therapeutic target                                      | Ref  |
|--------------------------------|----------------------------------------------|----------------------------------------------------------|------|
| Surgery and hemorrhage shock   | Comirnaty CP40                               | Complement protein C3 inhibition                         | [153,154] |
|                                | Artificial support to liver and kidney       | Alternative to renal replacement therapy                | [155] |
| Ischemia/reperfusion           | Erythropoietin                               | Anti-inflammatory                                        | [156] |
|                                | FR26030                                     | Inhibits INOS and inflammation                           | [157] |
|                                | Monoclonal antibody mAb107                   | Inhibits proinflammatory integrin                        | [158] |
|                                | Mesenchymal stem cells therapy               | Paracrine effects, transdifferentiation                  | [159] |
| Drugs (e.g. Cisplatin gentamycin)| Mesenchymal stem cells therapy               | Repair and renewal of cells in the kidney                | [160] |
|                                | Anti-TNF-α antibody                          | Anti-inflammatory and reduces coagulation                | [165] |
|                                | Fondaparinux pentasaccharide                 | Anticoagulant, inhibits Factor Xa                         | [166] |
|                                | Diethylentriamine pentaacetic acid           | Chelates iron and reduces oxidative radicals             | [167] |

### Table 3. Major therapeutic approaches tested in ovines.

| Model                          | Therapy                                      | Therapeutic target                                      | Ref  |
|--------------------------------|----------------------------------------------|----------------------------------------------------------|------|
| Sepsis                         | TAK-242 inhibitor of Toll Like receptor 4   | Interrupts LPS activation                                 | [168] |
|                                | receptor 4 (TLR4)                            |                                                          |      |
|                                | Deoximethadone, α2-adrenergic receptor agonist | Adjunct therapy to norepinephrine infusion, reduces IL-6, increases IL-10 | [169] |
|                                | Furosemide                                   | Diuretic increases sodium excretion, decreases oxygen consumption | [170] |
|                                | Arginine vasopressin (AVP) and norepinephrine (NE) | Improves blood pressure and renal blood flow | [171,172] |
|                                | Angiotensin II                               | Vasoconstrictor improves blood flow and creatinine clearance | [173] |
|                                | Various resuscitation fluids                 | Improves blood volume and pressure                       | [174–175] |
|                                | Ketamine, NMDA receptor antagonists          | Reduces inflammation, macrophages infiltration          | [176] |
|                                | organic mononitrites of 1,2-propanediol (PDNO) | Vasodilator, improves oxygen utilization in kidneys     | [177] |
|                                | Zinc                                         | Cyto-protective, upregulates hypoxia inducible factor proteins, not clear | [178] |
|                                | Mesenchymal stem cells                       | Not effective in the sheep model                        | [179] |
| Cardiopulmonary bypass         | Metaraminol, α1-adrenergic receptor agonist  | Improves oxygenation in renal medulla                    | [180] |
| Hemorrhage shock               | 7.5% NaCl/6% Dextran-70 (HSD) as resuscitation fluid | Improves plasma volume, hemodynamics and safe during dehydration | [181] |
of atrial natriuretic peptide might be effective in preventing or treating AKI [202].

Mesenchymal stem/stromal cell (MSC) therapy has shown promise in ameliorating AKI and stimulating cellular repair in rodents [203]. Emerging evidence has demonstrated similar results in LAM. MSC exhibit recovery and protective function associated with an increase of FoxP3⁺ Treg in cisplatin-induced AKI in Macaque mulatta [160]. By reducing renal expression of NF-κB, TNF-α, IFN-γ, MCP-1, and oxidative stress, MSC restores kidney function in atherosclerotic renal artery stenosis-induced AKI in pigs [127]. The main obstacles that must be addressed with MSC are the safety, dose, source of cells, and delivery methods [187,204]. To circumvent some of these obstacles, Lerman and colleagues have shown that intrarenal delivery of MSC extracellular vesicles achieves similar results as MSC in the attenuation of AKI in pigs [128–130]. However, more research is needed.

**Limitations of LAM in AKI studies**

Because tools such as genetic modification, monoclonal antibodies, and commercial test kits are not as widely available in LAM as they are in murine models, LAM have been used less for mechanistic inquiries. Further, the high costs of housing, longer breeding cycle, laborious surgical procedures, and animal welfare guidelines discourage the frequent use of LAM. Moreover, the technical expertise needed to surgically manipulate these animals is also challenging. Therefore, LAM is often only utilized for studying AKI for translational purposes. This results in a lack of sufficient knowledge to understand innate and adaptive immune responses behind the results and hinders follow-up studies to refine testing.

While LAM are more similar to each other than they are to rodents, immunology, and physiology still differs among the different species. Therefore, an intervention might not be equally effective in different species of LAM. For example, MSC therapy is reported to be effective in dogs and pigs [187] but not in cats [183] or sheep [179]. Even among the same species, the same treatment can have different results in different AKI models. For example, ATP-MgCl₂ was reported to improve I/R-induced AKI [190] but worsen cisplatin-induced nephrotoxicity [191] in dogs. Moreover, in order to induce AKI over a short time frame, the dose of a toxin used in LAM is usually higher than the equivalent dose in humans. The above considerations suggest that a multi-species, staged approach to examine mechanism and efficacy with focused etiological uses would be beneficial.

**Interventions of AKI tested in the porcine models**

Use of pigs for biomedical studies was recorded as early as 162 AD when Romans dissected pigs to gain a greater understanding of human physiology [205]. Today, pigs are becoming more and more popular subjects in biomedical research including kidney research (Figure 1). In addition to the immunologic similarities described above, this is due to their out breed nature, proximity to human physical size, and similar anatomy.

| Model | Animal | Therapy | Therapeutic target | Ref |
|-------|--------|---------|-------------------|-----|
| Sepsis | Dogs | Recombinant human brain natriuretic peptide (rhBNP) | Improves renal blood flow by NO generation | [182] |
| IRI | Cats | Mesenchymal stem cell therapy | No therapeutic effects | [183] |
| | Dogs | CRRL269, guanylyl cyclase A receptor peptide activator | Reduces apoptosis, modulation of intracellular Ca²⁺ levels | [184] |
| | Dogs | Vitamin C | Antioxidant, reduces BUN values, not completely effective | [185] |
| Dogs | Sildenafil | Anti-inflammatory, antioxidant and anti-apoptotic | [186] |
| Dogs | Mesenchymal stem cells therapy combination therapy (n-acetyl cysteine (NAC) + sodium nitroprusside (SNP) + phosphormidon) | Repair the renal tissues | [187] |
| Dogs | Prostaglandin E2 (PGE2) | Antioxidant, vasodilator, endothelin inhibitor | [188] |
| Dogs | ATP-MgCl₂ | Creatine and urea clearances were improved but the exact mechanism is not clear | [189] |
| Drug | Dogs | ATP-MgCl₂ | Improves energy metabolism, claimed to be useful in humans also | [190] |
| Drug | Dogs | ATP-MgCl₂ | Worsens the renal parameters not useful, contradicts the IRI model results | [191] |
| Hemorrhage shock | Dogs | Atrial natriuretic factor (ANF) | Increases and maintains GFR | [192] |
| Hemorrhage shock | Dogs | Fenoldopam | Dopamine D₁ receptor agonist, improves blood flow | [193] |

**Table 4. Major therapeutic approaches tested in felines and canines.**
and physiology. Unlike herbivorous rodents, pigs are omnivorous, an advantage to studying the role of gut microbiota in human AKI [95].

Vasculature plays a pivotal role in AKI. Swine kidneys are pyramidal and multilobar with vascular structure comparable to human kidneys, while mice and rats have unilobular kidneys [206]. The anatomy of the swine kidney is actually more similar to humans than that of NHP [207]. The length of renal arteries of large animals is closer to human renal artery length than rodent renal artery length. The average human renal artery is 10.4 cm long, whereas the length of a rat renal artery is only 1.54 cm. In contrast, the average length of the renal artery is 6.1 cm for goats, 3.84 cm for monkeys, and 3.01 cm for pigs [208,209]. Further, pigs have similar renal blood flow rate, resistance index, pulsatility index, and systolic/diastolic index as humans [210]. In the renal superficial veins, humans, cats, and dogs are reported to have ‘stellate veins’, whereas rats have only spur like veins [211]. The porcine renal function analytes such as creatinine, blood urea nitrogen (BUN) and anion secretion [22,23,212] are comparable to human’s. The size of pigs as well as other LAM allow for the serial collection of blood analysis for biomarkers. The National Swine Resource and Research Center (NSRRC) offers triple knockouts and selected transgenic porcine models to facilitate translational research and potential for xenotransplantation [213]. Many markers are available to characterize pig immune cells. Moreover, pigs have been used to troubleshoot isolation of renal progenitor cells, and have been used to examine the effectiveness of these cells [214–216].

While adult domestic pigs are large, difficult to handle, and take a long time to breed, small breeds of pigs offer an alternative that mitigate some of these limitations [206]. In porcine AKI studies, fitting a dose (or ischemic time) with AKI score curve severity is difficult because the sample size is often small. Many therapeutics and their targets that have been tested in swine models to date are summarized in Table 1. Some of the therapeutics listed in the table are preventative, pre-treatment, or concomitantly administered, while others are responsive and given as treatment after AKI is established. It is worth mentioning that pigs are traditionally bred for higher fat deposition, which may be protective for AKI [217]. However, in humans obesity is a well-known risk factor for AKI [218].

**Therapies tested in the NHP AKI models**

The number of publications utilizing NHP in the kidney research, including AKI, is low (Figure 1). One of the reasons is that due to ethical concerns, testing will only be justified when the treatment or drug has proved effective in other models. The NHP models are often designed for combined clinical insults such as trauma, blood loss, and sepsis, therefore, the injuries are not limited to the kidney. Multiple therapies have shown to improve renal function in NHP AKI models (Table 2). They include cytokine blockade, passive immunotherapy, stem cells, and erythropoietin. Unlike mice [219] and pigs [220,221], miRNA therapies are seldom examined in NHP [222,223]. This is likely because targets and specific gene expression are not well characterized in the renal tissues. Furthermore, kidney targeted drug delivery vehicles are not available [224,225].

**Interventions of AKI tested in ovine models**

Publications on the use of sheep models in kidney research, including testing therapies for AKI, are fewer compared to those using pigs but more than publications on the use of cats and dogs combined (Figure 1). One of the reasons is that sheep are an agricultural animal and easier to get approval for studies than cats and dogs. Therapeutics tested in the ovine models are listed in Table 3. The majority of publications are from May and colleagues from Australia.

**Interventions of AKI tested in the feline and canine models**

Studies of AKI in cats and dogs are significant in the field of veterinary medicine, but we limited our search to studies relevant for translational purposes. The search results are listed in Table 4. Cats and dogs are not widely used as models of translational AKI research because of ethical guidelines.

**Conclusion**

While they are the most commonly used animal models for AKI research, rats and mice have significantly different immune responses and anatomy compared to humans. This heterogeneity is one reason why promising therapeutics developed and tested in these animal models have failed to translate into clinical practice. In contrast, LAM have similarities to humans that may confer advantages when considering potential therapeutics for clinical studies. However, even large animals are not perfect replicas for human AKI. Further, animal experiments are planned in advance and carefully controlled, which is different from the clinical setting where AKI is multifactorial and patients have more variability.
in terms of comorbidities, age, gender, and genetic diversity [226]. Despite these limitations, the knowledge gleaned from LAM studies has the potential to advance our understanding of the basic pathophysiologic mechanisms of AKI in higher-order animals and to serve as a bridge between murine models and clinical trials.

**Disclosure statement**

Authors declare no conflict of interest. The content and views expressed in this article are the sole responsibility of the authors and do not necessarily reflect the views or policies of the Department of Defense or US Government. Mention of trade names, commercial products, or organizations does not imply endorsement by the Department of Defense or U.S. Government.

**References**

[1] Stewart IJ, Kosnov JA, Howard JT, et al. Acute kidney injury in critically injured combat veterans: a retrospective cohort study. Am J Kidney Dis. 2016;68(4):564–570.

[2] Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81(5):442–448.

[3] Hsu CY, Hsu RK, Yang J, et al. Elevated BP after AKI. JASN. 2016;27(3):914–923.

[4] Stewart IJ, Kosnov JA, Howard JT, et al. Retrospective analysis of long-term outcomes after combat injury: a hidden cost of war. Circulation. 2015;132(22):2126–2133.

[5] Bansal N, Matheny ME, Greevy RA, et al. Acute kidney injury and risk of incident heart failure among US veterans. Am J Kidney Dis. 2018;71(2):236–245.

[6] Go AS, Hsu CY, Yang J, et al. Acute kidney injury and risk of heart failure and atherosclerotic events. Clin J Am Soc Nephrol. 2018;13(6):833–841.

[7] Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. JASN. 2010;21(2):345–352.

[8] Sawhney S, Marks A, Fluck N, et al. Intermediate and long-term outcomes of survivors of acute kidney injury episodes: a large population-based cohort study. Am J Kidney Dis. 2017;69(1):18–28.

[9] Zarjou A, Sanders PW, Mehta RL, et al. Enabling innovative translational research in acute kidney injury. Clin Transl Sci. 2012;5(1):93–101.

[10] Di Giorno C, Pinheiro HS, Heinke T, et al. Beneficial effect of N-acetyl-cysteine on renal injury triggered by ischemia and reperfusion. Transplant Proc. 2006;38(9):2774–2776.

[11] Campos R, Shimizu MH, Volpini RA, et al. N-acetylcysteine prevents pulmonary edema and acute kidney injury in rats with sepsis submitted to mechanical ventilation. Am J Physiol Lung Cell Mol Physiol. 2012;302(7):L640–50.

[12] Kim JH, Lee SS, Jung MH, et al. N-acetylcysteine attenuates glycerol-induced acute kidney injury by regulating MAPKs and Bcl-2 family proteins. Nephrol Dial Transplant. 2010;25(5):1435–1443.

[13] Yenicerioglu Y, Yilmaz O, Sarioglu S, et al. Effects of N-acetylcysteine on radiocontrast nephropathy in rats. Scand J Urol Nephrol. 2006;40(1):63–69.

[14] Amini M, Salarifar M, Amribagloo A, et al. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials. 2009;10:45.

[15] Badri S, Soltani R, Sayadi M, et al. Effect of N-acetylcysteine against vancomycin-induced nephrotoxicity: a randomized controlled clinical trial. Arch Iran Med. 2020;23(6):397–402.

[16] Pereira JEG, El Dib R, Braz LG, et al. N-acetylcysteine use among patients undergoing cardiac surgery: a systematic review and meta-analysis of randomized trials. PLoS One. 2019;14(5):e0213862.

[17] Adabag AS, Ishani A, Koneswaran S, et al. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. Am Heart J. 2008;155(6):1143–1149.

[18] Mei M, Zhao HW, Pan QG, Pu YM, et al. Efficacy of N-acetylcysteine in preventing acute kidney injury after cardiac surgery: a meta-analysis study. J Invest Surg. 2018;31(1):14–23.

[19] Skropnyk NI, Siskind LJ, Faubel S, et al. Bridging translation for acute kidney injury with better preclinical modeling of human disease. Am J Physiol Renal Physiol. 2016;310(10):F972–84.

[20] de Caestecker M, Humphreys BD, Liu KD, et al.; ASN AKI Advisory Group. Bridging translation by improving preclinical study design in AKI. J Am Soc Nephrol. 2015;26(12):2905–2916.

[21] Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–2738.

[22] Meurers F, Summerfield A, Nauwynck H, et al. The pig: a model for human infectious diseases. Trends Microbiol. 2012;20(1):50–57.

[23] Dawson HD, Smith AD, Chen C, et al. An in-depth comparison of the porcine, murine and human inflammasomes; lessons from the porcine genome and transcriptome. Vet Microbiol. 2017;202:2–15.

[24] Smirnova I, Poltorak A, Chan EK, et al. Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol. 2000;1(1):RESEARCH002.

[25] Barreiro LB, Marioni JC, Blekhman R, et al. Functional comparison of innate immune signaling pathways in primates. PLoS Genet. 2010;6(12):e1001249.

[26] Star RA. Treatment of acute renal failure. Kidney Int. 1998;54(6):1817–1831.

[27] Chopra TA, Brooks CH, Okusa MD. Acute kidney injury prevention. Contrib Nephrol. 2016;187:9–23.

[28] Zuk A, Bonventre JV. Acute kidney injury. Annu Rev Med. 2016;67:293–307.

[29] Burmeister DM, Gomez BI, Dubick MA. Molecular mechanisms of trauma-induced acute kidney injury: Inflammatory and metabolic insights from animal models. Biochim Biophys Acta Mol Basis Dis. 2017;1863(10 Pt B):2661–2671.
[30] Yang Y, Song M, Liu Y, et al. Renoprotective approaches and strategies in acute kidney injury. Pharmacol Ther. 2016;163:58–73.

[31] Agarwal A, Dong Z, Harris R, et al.; Acute Dialysis Quality Initiative XIII Working Group. Cellular and molecular mechanisms of aKI. J Am Soc Nephrol. 2016;27(5):1288–1299.

[32] Rosin DL, Okusa MD. Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol. 2011;22(3):416–425.

[33] Ishimoto Y, Iagari R. Mitochondria: a therapeutic target in acute kidney injury. Nephrol Dial Transplant. 2016;31(7):1062–1069.

[34] Li L, Okusa MD. Macrophages, dendritic cells, and kidney ischemia-reperfusion injury. Semin Nephrol. 2010;30(3):268–277.

[35] Jang HR, Rabb H. Immune cells in experimental acute kidney injury. Nat Rev Nephrol. 2015;11(2):88–101.

[36] Wohlfahrtova M, Tycova I, Honsova E, et al. Molecular patterns of subclinical and clinical rejection of kidney allograft: quantity matters. Kidney Blood Press Res. 2015;40(3):244–257.

[37] Lever JM, Hull TD, Boddu R, et al. Resident macrophages reprogram toward a developmental state after acute kidney injury. JCI Insight. 2019;4(2):e125503.

[38] Prasada R, Muktesh G, Samanta J, et al. Natural history and profile of selective cytokines in patients of acute pancreatitis with acute kidney injury. Cytokine. 2020;133:155177.

[39] de Fontnouvelle CA, Greenberg JH, Thissen-Philbrook HR, et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury after pediatric cardiac surgery. Ann Thorac Surg. 2017;104(6):2072–2079.

[40] Sirotz JC, Walcher A, Faubel S, et al. Urine IL-18, NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver transplantation. BMC Nephrol. 2013;14:17.

[41] Iwakura T, Zhao Z, Marschner JA, et al. Dipetidyl peptidase-4 inhibitor teneligliptin accelerates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration. Nephrol Dial Transplant. 2019;34(10):1669–1680.

[42] Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases. UMS. 2018;19(6):1801.

[43] Huen SC, Cantley LG. Macrophages in renal injury and repair. Annu Rev Physiol. 2017;79:449–469.

[44] Zschaler J, Schlorke D, Arnhold J. Differences in innate immune response between man and mouse. Crit Rev Immunol. 2014;34(5):433–454.

[45] Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 2007;292(1):F116–F22.

[46] Ejaz AA, Dass B, Lingegowda V, et al. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. Int Urol Nephrol. 2013;45(2):449–458.

[47] Ding C, Han F, Xiang H, et al. Probiotics ameliorate renal ischemia-reperfusion injury by modulating the phenotype of macrophages through the IL-10/GSK-3β/PTEN signaling pathway. Pflugers Arch. 2019;471(4):573–581.

[48] Kim MG, Lim K, Lee YJ, et al. M2 macrophages predict worse long-term outcomes in human acute tubular necrosis. Sci Rep. 2020;10(1):2122.

[49] Palmer MB, Vichot AA, Cantley LG, et al. Quantification and localization of M2 macrophages in human kidneys with acute tubular injury. Int J Nephrol Renovasc Dis. 2014;7:415–419.

[50] Hu W, Lin J, Lian X, et al. M2a and M2b macrophages predominate in kidney tissues and M2 subpopulations were associated with the severity of disease of IgAN patients. Clin Immunol. 2019;205:8–15.

[51] Costa JS, Alves R, Sousa V, et al. Fibrogenesis in kidney transplant: dysfunction progress biomarkers. Transplant Proc. 2017;49(4):787–791.

[52] Li J, Liu CH, Xu DL, et al. Significance of CD163-positive macrophages in proliferative glomerulonephritis. Am J Med Sci. 2015;350(5):387–392.

[53] Wang S, Zhang C, Li J, et al. Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization. Cell Death Dis. 2017;8(4):e2725.

[54] Russell PS, Hong J, Windsor JA, et al. Renal lymphatics: anatomy, physiology, and clinical implications. Front Physiol. 2019;10:251.

[55] Pabst R. The pig as a model for immunology research. Cell Tissue Res. 2020;382(2):287–304.

[56] Fairbairn L, Kapetanovic R, Sester DP, et al. The mononuclear phagocyte system of the pig as a model for understanding human innate immunity and disease. J Leukoc Biol. 2011;89(6):855–871.

[57] Gómez BI, Harrington BK, Chao T, et al. Impact of oral resuscitation on circulating and splenic leukocytes after burns. Burns. 2020;46(3):567–578.

[58] Reynolds PS, Fisher BJ, McCarter J, et al. Interventional vitamin C: a strategy for attenuation of coagulopathy and inflammation in a swine multiple injuries model. J Trauma Acute Care Surg. 2018;85(15 Suppl 2):S57–S567.

[59] Castellan G, Melchiorre R, Loverre A, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010;176(4):1648–1659.

[60] Thomas AV, Broers AD, Vandegeaart HF, et al. Genomic structure, promoter analysis and expression of the porcine (Sus scrofa) TLR4 gene. Mol Immunol. 2006;43(6):653–659.

[61] Vaeur C, Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front Immunol. 2014;5:316.

[62] Tohno M, Shimazu T, Aso H, et al. Molecular cloning and functional characterization of porcine MyD88 essential for TLR signaling. Cell Mol Immunol. 2007;4(5):369–376.
of neonatal hypoxia-reoxygenation. Shock. 2015; 43(1):99–105.

[98] Goebel U, Siepe M, Schwer CI, et al. Inhaled carbon monoxide prevents acute kidney injury in pigs after cardiopulmonary bypass by inducing a heat shock response. Anesth Analgesia. 2010;111(1):29–37.

[99] Patel NN, Toth T, Jones C, et al. Prevention of post-cardiopulmonary bypass acute kidney injury by endothelin A receptor blockade. Critic Care Med. 2011;39(4):793–802.

[100] Patel NN, Lin H, Toth T, et al. Phosphodiesterase-5 inhibition prevents postcardiopulmonary bypass acute kidney injury in swine. Ann Thoracic Surg. 2011;92(6):2168–2176.

[101] Wang X, Xue Q, Yan F, et al. Ulinastatin protects against acute kidney injury in infant piglets model undergoing surgery on hypothermic low-flow cardiopulmonary bypass with deep hypothermic circulatory arrest. Sci Rep. 2019;9(1):1–14.

[102] Barrera-Chimal J, André-Grégoire G, Nguyen Dinh Cat A, et al. Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1. J Am Soc Nephrol. 2017;28(4):1216–1226.

[103] Davidson JA, Khailova L, Treece A, et al. Protective role of selectin ligand inhibition in a large animal model of kidney ischemia-reperfusion injury. Kidney Int. 2006;69(10):1749–1755.

[104] Sølling C, Christensen AT, Krag S, et al. Erythropoietin administration is associated with short-term improvement in glomerular filtration rate after ischaemia-reperfusion injury. Acta Anaesthesiol Scand. 2011;55(2):185–195.

[105] Simon F, Scheuerle A, Grüger M, et al. Effects of intravenous sulfide during porcine aortic occlusion-induced kidney ischemia/reperfusion injury. Kidney Int. 2006;98(1):197–210.

[106] Gozdzik W, Zielinski S, Zielinska M, et al. Beneficial effects of inhaled nitric oxide with intravenous steroids on renal function in an isolated pig kidney model. Eur J Vasc Endovasc Surg. 2011;41(6):723–727.

[107] Xu M, Wang X, Banan B, et al. Anti-CD47 monoclonal antibody therapy reduces ischemia-reperfusion injury of renal allografts in a porcine model of donation after cardiac death. Am J Transplant. 2018;18(4):855–867.

[108] Kolsrud O, Damén T, Nygren A, et al. Effects of atrial natriuretic peptide on renal function during cardiopulmonary bypass: a randomized pig model. Eur J Cardiothorac Surg. 2020;57(4):652–659.

[109] Miller Q, Peyton BD, Cohn EJ, et al. The effects of intraoperative fenoldopam on renal blood flow and tubular function following supraprenal aortic cross-clamping. Ann Vasc Surg. 2003;17(6):656–662.

[110] Gozdzik W, Zielinski S, Zielinska M, et al. Beneficial effects of inhaled nitric oxide with intravenous steroid in an ischemia-reperfusion model involving aortic clamping. Int J Immunopathol Pharmacol. 2018;32:394632017751486.

[111] Cau J, Favreau F, Tillement JP, et al. Trimetazidine reduces early and long-term effects of experimental renal warm ischemia: a dose effect study. J Vasc Surg. 2008;47(4):852–860.

[112] Kim M-J, Lee S-J, Park C-S, et al. Attenuation of renal ischemia-reperfusion injury by antioxidant vitamins in pigs. J Vet Clin. 2007;24(2):94–98.
[127] Eirin A, Zhu XY, Krier JD, et al. Adipose tissue-derived mesenchymal stem cells improve revascularization outcomes to restore renal function in swine atherosclerotic renal artery stenosis. Stem Cells. 2012;30(5):1030–1041.

[128] Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges. Stem Cell Res Ther. 2017;8(1):273.

[129] Eirin A, Zhu XY, Puranik AS, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int. 2017;92(1):114–124.

[130] Zhao Y, Zhu X, Zhang L, et al. Mesenchymal stem/stromal cells and their extracellular vesicle progeny decrease injury in post-stenotic swine kidney through different mechanisms. Stem Cells Dev. 2020;29(18):1190–1200.

[131] Doulamis IP, Guarianto A, Duignan T, et al. Mitochondrial transplantation by intra-arterial injection for acute kidney injury. Am J Physiol Renal Physiol. 2020;319(3):F403–F413.

[132] Kishi S, Campanholle G, Gohil VM, et al. Meclizine preconditioning protects the kidney against ischemia-reperfusion injury. EBioMedicine. 2015;2(9):1090–1101.

[133] Johnson ST, Bigam DL, Emara M, et al. N-acetylcysteine improves the hemodynamics and oxidative stress in hypoxic newborn pigs reoxygenated with 100% oxygen. Shock. 2007;28(4):484–490.

[134] Lee TF, Liu JQ, Li YQ, et al. Improved renal recovery with postresuscitation N-acetylcysteine treatment in asphyxiated newborn pigs. Shock. 2011;35(4):428–433.

[135] Kuntscher V, Treska V, Racek J, et al. Does the administration of antioxidants as scavengers of reactive oxygen species in kidney transplantation really have sense? Bratisl Lek Listy. 2007;108(9):385–387.

[136] Soussi D, Danion J, Baulier E, et al. Meclizine preconditioning protects the kidney against ischemia-reperfusion injury. Int Immunopharmacol. 2020;87:2321.

[137] Kim SR, Erin A, Zhang X, et al. Mitochondrial protection partly mitigates kidney cellular senescence in swine atherosclerotic renal artery stenosis. Cell Physiol Biochem. 2019;52(3):617.

[138] Amdisen C, Keller AK, Hansen RS, et al. Testing dengapptide effects on kidney function after ischemia/reperfusion injury in a new porcine two week model. PLoS One. 2016;11(10):e0164109.

[139] Soni H, Peixoto-Neves D, Olushoga MA, et al. Pharmacological inhibition of TRPV4 channels protects against ischemia-reperfusion-induced renal insufficiency in neonatal pigs. Clin Sci (Lond). 2019;133(9):CS20180815.

[140] Cui J, Bai X-Y, Sun X, et al. Rapamycin protects against gentamicin-induced acute kidney injury via autophagy in mini-pig models. Sci Rep. 2015;5:11256.

[141] Kumar G, Solanki MH, Xue X, et al. Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol. 2017;313(2):F339–F350.

[142] Wu J, Wan X, Zhang H, et al. Retinoic acid attenuates contrast-induced acute kidney injury in a miniature pig model. Biochem Biophys Res Commun. 2019;512(2):163–169.

[143] Xu J, Ma L, Fu P. MicroRNA-30c attenuates contrast-induced acute kidney injury by suppressing NLRP3 inflammasome. Int Immunopharmacol. 2020:87:106457.

[144] Cui J, Tang L, Hong Q, et al. N-acetylcysteine ameliorates gentamicin-induced nephrotoxicity by enhancing autophagy and reducing oxidative damage in miniature pigs. Shock. 2019;52(6):622–630.

[145] Junot S, Keroak S, Del Castillo JR, et al. Inhaled nitric oxide prevents NSAID-induced renal impairment in pseudo-normovolaemic piglets. PloS One. 2017;12(6):e0179475.

[146] Wagner KE, Martinez JM, Vath SD, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med. 2002;30(10):2313–2321.

[147] Solling C, Christensen AT, Nygaard U, et al. Erythropoietin does not attenuate renal dysfunction or inflammation in a porcine model of endotoxemia. Acta Anaesthesiol Scand. 2011;55(4):411–421.

[148] Yeh YC, Yu LC, Wu CY, et al.; NTUH Center of Microcirculation Medical Research (NCMMR). Effects of endotoxin absorber hemoperfusion on microcirculation in septic pigs. J Surg Res. 2017;211:242–250.

[149] Kubiak BD, Albert SP, Gatto LA, et al. Peritoneal negative pressure therapy prevents multiple organ injury in a chronic porcine sepsis and ischemia/reperfusion model. Shock. 2010;34(5):525–534.

[150] Gomez BI, McIntyre MK, Gurney JM, et al. Enteral resuscitation with oral rehydration solution to reduce acute kidney injury in burn victims: evidence from a porcine model. PLoS One. 2018;13(5):e0195615.

[151] Smith S, Behrens B, McCully B, et al. Aggressive treatment of acute kidney injury and hyperkalemia improves survival in a combat relevant trauma model in swine. Am J Surg. 2020;219(5):860–864.

[152] de Castro LUC, Ida KK, Otsuki DA, et al. Vasopressin analog terlipressin attenuates kidney injury in hemorrhagic shock. Trauma Surg Acute Care Open. 2016;1(1):e000039.

[153] van Griensven M, Ricklin D, Denk S, et al. Protective effects of the complement inhibitor compstatin CP40 in hemorrhagic shock. Shock. 2019;51(1):78–87.

[154] Hallegbe Rauer R, Karasu E, Braun CK, et al. Thirty-eight-negative kinase 1 is a mediator of acute kidney injury in experimental and clinical traumatic hemorrhagic shock. Front Immunol. 2020:11:2081.

[155] van Griensven M, Ricklin D, Denk S, et al. Protective effects of the complement inhibitor compstatin CP40 in hemorrhagic shock. Shock. 2019;51(1):78–87.

[156] Ishii Y, Sawada T, Murakami T, et al. Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model. Nephrol Dial Transplant. 2011;26(4):1157–1162.

[157] Qi S, Xu D, Ma A, et al. Effect of a novel inducible nitric oxide synthase inhibitor, FR260330, in
prevention of renal ischemia/reperfusion injury in vervet monkeys. Transplantation. 2006;81(4):627–631.

[158] Dehndi A, Benedict Cosimi A, Neal Smith R, et al. Prophylactic orthosteric inhibition of leukocyte integrin CD11b/CD18 prevents long-term fibrotic kidney failure in cynomolgus monkeys. Nat Commun. 2017;8:13899.

[159] Lee KW, Kim TM, Kim KS, et al. Renal ischemia-reperfusion injury in a diabetic monkey model and therapeutic testing of human bone marrow-derived mesenchymal stem cells. J Diabetes Res. 2018;2018:5182606.

[160] Mughadasali R, Azarnia M, Hajinasrollah M, et al. Intra-renal arterial injection of autologous bone marrow mesenchymal stromal cells ameliorates cisplatin-induced acute kidney injury in a rhesus Macaque mulatta monkey model. Cytotherapy. 2014;16(6):734–749.

[161] Gautier J-C, Zhou X, Yang Y, et al. Evaluation of novel biomarkers of nephrotoxicity in Cynomolgus monkeys treated with gentamicin. Toxicol Appl Pharmacol. 2016;303:1–10.

[162] Chen Y, Thurman JD, Kinter LB, et al. Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys. Toxicol Appl Pharmacol. 2017;336:66–74.

[163] Welty-Wolf KE, Carraway MS, Ortel TL, et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced renal failure. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L21–31.

[164] Stearns-Kurosawa DJ, Collins V, Freeman S, et al. Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide. Pediatr Nephrol. 2011;26(11):2031–2039.

[165] Fiedler VB, Loof I, Sander E, et al. Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med. 1992;120(4):574–588.

[166] Keshari RS, Silasi R, Popescu NI, et al. Fondaparinux pentasaccharide reduces sepsis coagulopathy and promotes survival in the baboon model of Escherichia coli sepsis. J Thromb Haemost. 2020;18(1):180–190.

[167] Molina L, Studenberg S, Wolberg G, et al. Efficacy of treatment with the iron (III) complex of diethylenetriamine pentaacetic acid in mice and primates inoculated with live lethal dose 100 Escherichia coli. J Clin Invest. 1996;98(1):192–198.

[168] Fenhammar J, Rundgren M, Forestier J, et al. Toll-like receptor 4 inhibitor TAK-242 attenuates acute kidney injury in endotoxemic sheep. Anesthesiol J Am Soc Anesthesiol. 2011;114(S):1130–1137.

[169] Lankadeva YR, Ma S, Iguchi N, et al. Dexametomidine reduces norepinephrine requirements and preserves renal oxygenation and function in ovine septic acute kidney injury. Kidney Int. 2019;96(5):1150–1161.

[170] Iguchi N, Lankadeva YR, Mori TA, et al. Furosemide reverses medullary tissue hypoxia in ovine septic acute kidney injury. Am J Physiol Regul Integr Comp Physiol. 2019;317(2):R232–R239.

[171] Post EH, Su F, Rigby Shinotsuka C, et al. Renal autorregulation in experimental septic shock and its response to vasopressin and norepinephrine administration. J Appl Physiol (1985). 2018;125:1661–1669.

[172] Okazaki N, Iguchi N, Evans RG, et al. Beneficial effects of vasopressin compared with norepinephrine on renal perfusion, oxygenation, and function in experimental septic acute kidney injury. Crit Care Med. 2020;48(10):e951–e958.

[173] Lankadeva YR, Kosaka J, Evans RG, et al. Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury. Crit Care Med. 2018;46(1):e41–e48.

[174] Lankadeva YR, Kosaka J, Iguchi N, et al. Effects of fluid bolus therapy on renal perfusion, oxygenation, and function in early experimental septic kidney injury. Critical Care Medicine. 2019;47(1):e36–e43.

[175] Orbegozo D, Su F, Santacruz C, et al. Effects of different crystalloid solutions on hemodynamics, peripheral perfusion, and the microcirculation in experimental abdominal sepsis. Anesthesiology. 2016;125(4):744–754.

[176] Chang El, Zaráte MA, Rabaglino MB, et al. Ketamine suppresses hypoxia-induced inflammatory responses in the late-gestation ovine fetal kidney cortex. J Physiol (Lond). 2016;594(5):1295–1310.

[177] Nilsson KF, Sandin J, Gustafsson LE, et al. The novel nitric oxide donor PDNO attenuates ovine ischemia/reperfusion induced renal failure. Intens Care Med. 2017;5(1):29.

[178] O’Kane D, Gibson L, May CN, et al. Zinc preconditioning protects against renal ischaemia reperfusion injury in a preclinical sheep large animal model. Biometals. 2018;31(5):821–834.

[179] Behr L, Hekmati M, Lucchini A, et al. Evaluation of the effect of autologous mesenchymal stem cell injection in a large-animal model of bilateral kidney ischaemia reperfusion injury. Cell Prolif. 2009;42(3):284–297.

[180] Lankadeva YR, Cochrane AD, Marino B, et al. Strategies that improve renal medullary oxygenation during experimental cardiopulmonary bypass may mitigate postoperative acute kidney injury. Kidney Int. 2019;95(6):1338–1346.

[181] Kampmeier T, Armemann P, Hessler M, et al. Effects of resuscitation with human albumin 5%, hydroxyethyl starch 130/0.4 6%, or crystalloid on kidney damage in an ovine model of septic shock. Br J Anaesth. 2018;121(3):581–587.

[182] Li N, Jin H-X, Song Z, et al. Protective effect of recombinant human brain natriuretic peptide on acute renal injury induced by endotoxin in canines. Cell Biochem Biophys. 2014;70(2):1317–1324.

[183] Rosselli DD, Mumaw JL, Dickerson V, et al. Efficacy of allogeneic mesenchymal stem cell administration in a model of acute ischemic kidney injury in cats. Res Vet Sci. 2016;108:18–24.

[184] Chen Y, Harty GJ, Zheng Y, et al. CRRL269: a novel particulate guanylyl cyclase A receptor peptide activator for acute kidney injury. Circ Res. 2019;124(10):1462–1472.
Danziger J, Chen K, Lee J, et al. Obesity, acute kidney injury, and mortality in critical illness. Critic Care Med. 2016;44(2):328.

Alidori S, Akhavein N, Thorek DJ, et al. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med. 2016;8(331):331ra39.

Yang C, Li L, Xue Y, et al. Innate immunity activation involved in unprotected porcine auto-transplant kidneys preserved by naked caspase-3 siRNA. J Transl Med. 2013;11(1):210.

Yang C, Yang B. siRNA-induced RNAi therapy in acute kidney injury. RNA Interf. 2016;223.

Thompson JD, Kornbrust DJ, Foy JW, et al. Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther. 2012;22(4):255–264.

Fan P-C, Chen C-C, Chen Y-C, et al. MicroRNAs in acute kidney injury. Hum Genomics. 2016;10(1):29.

Han SJ, Williams RM, D’Agati V, et al. Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury. Kidney Int. 2020;98(1):76–87.

Haas M, Kluppel ACA, Wartna ES, et al. Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo. Kidney Int. 1997;52(6):1693–1699.

Liu KD, Humphreys BD, Endre ZH. The ten barriers for translation of animal data on AKI to the clinical setting. Intensive Care Med. 2017;43(6):898–900.